PVR and cancer: In agreement with this finding, a pancancer analysis confirmed the high expression of CD155 in ESCA, as well as in other cancers, including cholangiocarcinoma, colon adenocarcinoma, and pancreatic adenocarcinoma (Figure 1C) (Supplementary Figure S2).